Literature DB >> 36149610

Dynamic Alteration in HLA-E Expression and Soluble HLA-E via Interaction with Natural Killer Cells in Gastric Cancer.

Takeshi Morinaga1, Masaaki Iwatsuki1, Kohei Yamashita1, Noriko Yasuda-Yoshihara1, Taishi Yamane1, Chihiro Matsumoto1, Kazuto Harada1, Kojiro Eto1, Junji Kurashige1, Takatsugu Ishimoto1, Yoshifumi Baba1, Yuji Miyamoto1, Naoya Yoshida1, Hideo Baba2.   

Abstract

BACKGROUND: Some reports showed the immune tolerance of soluble human leukocyte antigen E (HLA-E), but the role that soluble HLA-E plays in gastric cancer (GC) is unknown. We aimed to clarify the molecular mechanism and clinical significance of soluble HLA-E in GC.
METHODS: We examined the expression of HLA-E on GC cells and soluble HLA-E under co-culture with natural killer (NK) cells in a time-dependent manner. Changes in NK cell activity were investigated using anti-NK group 2 member A (NKG2A) antibodies in the presence of soluble HLA-E. Expression of soluble HLA-E in the serum of GC patients was determined.
RESULTS: Whereas HLA-E expression on GC cells peaked with interferon (IFN)-γ secretion by NK cells in a time-dependent manner, soluble HLA-E was upregulated in conditioned medium. Pre-incubation with anti-NKG2A antibodies increased the activation of NKG2A+ NK cells in the presence of soluble HLA-E. Expression of soluble HLA-E in the serum of GC patients correlated with disease progression.
CONCLUSIONS: HLA-E expression dynamically changes on GC cells and in conditioned medium. Furthermore, soluble HLA-E can contribute to immune escape in GC cell lines, which may have significance in clinical practice. Moreover, soluble HLA-E may be a potential prognostic biomarker.
© 2022. Society of Surgical Oncology.

Entities:  

Year:  2022        PMID: 36149610     DOI: 10.1245/s10434-022-12505-0

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   4.339


  1 in total

1.  Human leukocyte antigen (HLA)-E and HLA-F expression in gastric cancer.

Authors:  Sumiya Ishigami; Takaaki Arigami; Hiroshi Okumura; Yasuto Uchikado; Yoshiaki Kita; Hiroshi Kurahara; Kosei Maemura; Yuko Kijima; Yuka Ishihara; Ken Sasaki; Yoshikazu Uenosono; Shoji Natsugoe
Journal:  Anticancer Res       Date:  2015-04       Impact factor: 2.480

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.